Updates are available Correction dated 2023-06-01

Article History

Received: 28 July 2021

Accepted: 10 January 2023

First Online: 27 February 2023

Change Date: 1 June 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41467-023-38999-0

Competing interests

: The authors declare the following competing interests: J.C. reports employment and stock ownership with AstraZeneca. J.E.G. reports receiving honoraria from AstraZeneca, Genenech, Bristol-Myers Squibb, Takeda, EMD Serano Merck; and has received research grants/funding from AstraZeneca, Genentech, Bristol-Myers Squibb, BI, Takeda, Array, Merck. Y.C. reports no conflicts of interest. Y.O. reports undertaking an advisory role for AstraZeneca, Chugai, ONO, Bristol-Myers Squibb, Kyorin, Celltrion, Amgen, and Nippon Kayaku; reports receiving honoraria from AstraZeneca, Chugai, Eli Lilly, ONO, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer, Pfizer, MSD, Taiho, Nippon Kayaku, and Kyowa Hakko Kirin; and has received grants or funds from AstraZeneca, Chugai, Lilly, ONO, BMS, Kyorin, Dainippon- Sumitomo, Pfizer, Taiho, Novartis, Kissei, Ignyta, Takeda, Kissei, Daiichi-Sankyo, Janssen, and LOXO. F.I. has received honoraria and research funding from AstraZeneca. B.C.C. reports stock ownership with TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus Therapeutics, and Interpark Bio Convergence Corp; reports participating in an advisory role for KANAPH Therapeutic Inc, Brigebio Therapeutics, Cyrus Therapeutics, and Guardant Health; has received consulting fees from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, Bristol-Myers Squibb, ONO, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Janssen, Medpacto, and Blueprint medicines; has received grants or funds from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, ONO, Dizal Pharma, MSD, Abbvie, Medpacto, GI Innovation, Eli Lilly, Blueprint medicines, and Interpark Bio Convergence Corp; has received royalties from Campions Oncology; and is the founder of DAAN Biotherapeutics. M-C.L. is on the board of directors for AstraZeneca and Boehringer Ingelheim, has received honoraria from Roche; and has received consulting fees from AstraZeneca, Boehringer Ingelheim and MSD. M.M. has received honoraria from Bristol-Myers Squibb, MSD, Boehringer Ingelheim, AstraZeneca, Roche, Kyowa Kyrin, Pierre Fabre, Takeda, Bayer and has received research funding from Bristol-Myers Squibb. R.S. reports employment with the Maidstone and Tunbridge Wells NHS Trust; participated in an advisory role for AstraZeneca, Roche, Pfizer and Boehringer Ingelheim; and has received honoraria from AstraZeneca, Roche, Pfizer, and Boehringer Ingelheim. Y.R. reports employment and stock ownership with AstraZeneca. A.T. reports employment and stock ownership with AstraZeneca. A.M. reports employment and stock ownership with AstraZeneca. J.C.B. reports employment and stock ownership with AstraZeneca. R.J.H. reports employment and stock ownership with AstraZeneca. S.S.R. has participated in an advisory role for Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Tesaro, Takeda, GlaxoSmithKline, Daichii Sankyo, and Eisai; is on the board of directors for the International Association for Study of Lung Cancer; has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Tesaro, Takeda, GlaxoSmithKline, Daichii Sankyo, and Eisai; and has received grants or funds from Amgen, Advaxis, AstraZeneca, BMS, Merck, Tesaro, Takeda, and Genmab.